

Zydus receives final approval from the USFDA for Glyburide Tablets

Ahmedabad, 11 May 2016

Zydus Cadila has received the final approval from the USFDA to market Glyburide Tablets USP in strengths of 1.25, 2.5 and 5 mg. Glyburide, which is an anti-diabetic drug will be produced at the group's formulations manufacturing facility at Baddi.

The group now has more than 100 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.
